Eureka Therapeutics to Present New Clinical Data of anti-CD19 ARTEMIS™ 3.0 T-cell Therapy at 2019 ASH Annual Meeting

On December 3, 2019 Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T-cell therapies to treat cancers, reported that new clinical data from its first-in-human study of ET019003, an anti-CD19 T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL), will be presented in a poster session at the 61st American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting on December 8, 2019 (Press release, Eureka Therapeutics, DEC 3, 2019, View Source [SID1234551889]). ET019003 is engineered by incorporating a co-stimulatory molecule into T-cells expressing an anti-CD19 antibody T-cell receptor (AbTCR) core structure, representing the next generation of Eureka’s novel T-cell therapy generated with the ARTEMIS T-cell platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to be selected for poster presentation at the 2019 ASH (Free ASH Whitepaper) Meeting," said Dr. Cheng Liu, Founder & CEO of Eureka Therapeutics. "This is significant recognition of the progress we are making in the development of novel T cell therapies from our ARTEMIS platform, and we look forward to sharing additional updates from our additional programs at the conference."

Details of the poster presentation are as follows:

Title:


First-in-Human Study of ET019003, a Next Generation Anti-CD19 T-Cell Therapy, in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)

Publication:


2870

Session:


626

Date:


Sunday, December 8, 2019

Time:


6:00 – 8:00pm EST

Location:


Orange County Convention Center, Hall B

Presenter:


Pengcheng He, the First Affiliated Hospital of Xi’an Jiaotong University, China

The ASH (Free ASH Whitepaper) abstract is now available at www.hematology.org. The poster presentation will include additional data not available in the abstract.